Role of inflammation and immunity in depression

Author/s
Golam M. Khandaker, Edward T. Bullmore
Citation
Issue 5 Winter 2018
CEPiP.2018.1.26-31
Abstract

Monoamine based treatments of depression are only effective in a select population of patients. Under-standing the pathogenesis and mechanisms of depression may offer novel therapies where typical mon-oamine treatments fail. We present evidence for the role of low-grade systemic activation of the innate immune system in the pathogenesis of depression, antidepressant response, anti-inflammatory treat¬ment of depression, and physical comorbidities of depression. Cross-sectional studies have demonstrated a relationship between specific inflammatory blood biomarkers (IL-6, CRP and TNF-alpha) and depression. Longitudinal studies show inflammation is not an epiphenomenon of depression: inflammatory biomarkers precede depressive symptoms. Evidence from animal studies have detailed mechanisms whereby peripheral inflammatory signals are communicated to the brain, affecting mood, cognition and behaviour. Pharmacologically, a high IL-6 level predicts poor response to selective serotonin reuptake inhibitors and it remains elevated in non-responders, indicating inflammatory cytokines may underlie treatment-resistance. Furthermore, anti-cytokine treatments have substantial anti-depressant effects comparable to conventional antidepressant medication, at least in patients with co-morbid depression and high levels of peripheral inflammation. There is also evidence that inflammation links depression and physical illness, with elevated inflammatory markers mediating the relationship between depression and both childhood maltreatment and coronary heart disease. Clearly, the role of inflammation in depression is complex. To understand the relationship better, studies need to examine causality of the association and the efficacy of novel immunotherapies in depressed patients without chronic physical illness.

Cite as: Cutting Edge Psychiatry in Practice 2018, 5(1):26-31; https://doi.org/10.65031/ljcy4535

References

  1. Belmaker RH, Agam G. Major depressive disorder. New England Journal of Medicine. 2008 Jan 3;358(1):55-68. https://doi.org/10.1056/nejmra073096
  2. Nemeroff CB. Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry. 2007 Jul 16;68(8):17.      
  3. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience. 2008 Jan;9(1):46. https://doi.org/10.1038/nrn2297
  4. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry. 2009 May 1;65(9):732-41. https://doi.org/10.1016/j.biopsych.2008.11.029
  5. Bullmore E. The Inflamed Mind: A radical new approach to depression. Short Books; 2018 Apr 26.    
  6. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013 Sep 3;52(12):2136-48. https://doi.org/10.1093/rheumatology/ket169
  7. Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X, Langohr K, Solà R, Vieta E, Martín-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. The Journal of Clinical Psychiatry. 2012 Aug;73(8):1128-38. https://doi.org/10.4088/jcp.12r07694
  8. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmächer T. Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry. 2001 May 1;58(5):445-52. https://doi.org/10.1001/archpsyc.58.5.445
  9. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biological Psychiatry. 2009 Sep 1;66(5):407-14. https://doi.org/10.1016/j.biopsych.2009.03.015
  10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biological Psychiatry. 2010 Mar 1;67(5):446-57. https://doi.org/10.1016/j.biopsych.2009.09.033
  11. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain, Behavior and Immunity. 2015 Oct 1;49:206-15. https://doi.org/10.1016/j.bbi.2015.06.001
  12. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine. 2009 Feb 1;71(2):171-86. https://doi.org/10.1097/psy.0b013e3181907c1b
  13. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014 Oct 1;71(10):1121-8. https://doi.org/10.1001/jamapsychiatry.2014.1332
  14. Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, Kumari M, Lowe GD, Rumley A, Marmot MG, Ferrie JE. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychological Medicine. 2009 Mar;39(3):413-23. https://doi.org/10.1017/s0033291708003723
  15. Wium-Andersen MK, Nielsen SF. Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73á131 Individuals. JAMA Psychiatry. 2013 Feb 1;70(2):176-84. https://doi.org/10.1001/2013.jamapsychiatry.102
  16. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013 Jan 1;70(1):31-41. https://doi.org/10.1001/2013.jamapsychiatry.4
  17. Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. Journal of Affective Disorders. 2013 May 15;148(1):136-40. https://doi.org/10.1016/j.jad.2012.10.036
  18. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009 Jun 15;33(4):722-6. https://doi.org/10.1016/j.pnpbp.2009.03.020
  19. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997 Nov 1;9(11):853-8. https://doi.org/10.1006/cyto.1997.0238
  20. O’Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of Psychiatric Research. 2007 Apr 1;41(3- 4):326-31. https://doi.org/10.1016/j.jpsychires.2006.05.013
  21. Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint AM, Schwarz MJ, Tylee AT, Carvalho LA, Pariante CM. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain, Behavior and Immunity. 2015 Aug 1;48:8-18. https://doi.org/10.1016/j.bbi.2013.07.090
  22. Christmas DM, Potokar JP, Davies SJ. A biological pathway linking inflammation and depression: activation of indoleamine 2, 3-dioxygenase. Neuropsychiatric Disease and Treatment. 2011;7:431. https://doi.org/10.2147/ndt.s17573
  23. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J. Effect of anti-inflammatory treat ment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014 Dec 1;71(12):1381-91. https://doi.org/10.1001/jamapsychiatry.2014.1611
  24. Hu F, Wang X, Pace TW, Wu H, Miller AH. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Molecular Psychiatry. 2005 Feb 8;10(5):426. https://doi.org/10.1038/sj.mp.4001644
  25. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry. 2001 Mar 1;49(5):391-404. https://doi.org/10.1016/s0006-3223(00)01088-x
  26. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954-9. https://doi.org/10.1001/jama.286.8.954
  27. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLOS One. 2012 Jan 17;7(1):e30275. https://doi.org/10.1371/journal.pone.0030275
  28. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials. British Journal of Dermatology. 2012 Jan 1;166(1):179- 88. https://doi.org/10.1111/j.1365-2133.2011.10583.x
  29. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry. 2018 Feb;23(2):335. https://doi.org/10.1038/mp.2016.167
  30. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine. 2008 Feb 26;5(2):e45. https://doi.org/10.1371/journal.pmed.0050045
  31. Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, Sharp DJ, Araya R, Hollinghurst S, Peters TJ. Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. The Lancet. 2009 Aug 22;374(9690):628-34. https://doi.org/10.1016/s0140-6736(09)61257-5
  32. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation. 1996 Jun 1;93(11):1976-80. https://doi.org/10.1161/01.cir.93.11.1976
  33. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology. 1993 Jul 1:285-94. https://doi.org/10.1097/00001648-199307000-00003
  34. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLOS Medicine. 2008 Apr 8;5(4):e78. https://doi.org/10.1371/journal.pmed.0050078
  35. Barker DJ. The fetal and infant origins of adult disease. BMJ 1990 Nov 17;301(6761):1111. https://doi.org/10.1136/bmj.301.6761.1111
  36. Tzoulaki I, Jarvelin MR, Hartikainen AL, Leinonen M, Pouta A, Paldanius M, Ruokonen A, Canoy D, Sovio U, Saikku P, Elliott P. Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 Birth Cohort study. European Heart Journal. 2008 Apr 1;29(8):1049-56. https://doi.org/10.1093/eurheartj/ehn105
  37. Abel KM, Wicks S, Susser ES, Dalman C, Pedersen MG, Mortensen PB, Webb RT. Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies? Archives of General Psychiatry. 2010 Sep 1;67(9):923-30. https://doi.org/10.1001/archgenpsychiatry.2010.100
  38. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry. 2008 Apr 1;65(4):409-15. https://doi.org/10.1001/archpsyc.65.4.409